Dr. Harold Wodlinger
Harold Wodlinger is a Consultant to the Medical Device industry with more than twenty years of experience in engineering, operations, sales, and management. He has a proven track record in the areas of strategic planning, business and new product development, and due diligence. He has an extensive network of physician and industry thought leaders, development and research resources, and investment professionals.
Dr. Wodlinger was a co-founder of Biomedical Instrumentation Inc., a world leader in cardiology systems used to diagnose electrical problems within the heart. He acted as Project Manager for the company’s most successful product, a project that was completed on time and on budget, and was considered a major advance in the field.
Following a period of rapid growth, Biomedical Instrumentation was acquired by American Home Products Corp. Dr. Wodlinger led the negotiation with American Home Products for the sale of the company, and remained as President of the division, renamed Quinton Electrophysiology. There he guided the company through a period of rapid growth and major change, including adapting to new corporate culture, conformance to ISO 9001, CE listing, and adherence to new FDA standards. He increased sales by 110% with an income of 27% of sales in the first year post acquisition.
His experience in founding the company, developing products, manufacturing, marketing, and the negotiation of its acquisition have proven invaluable to his consulting clients.
Prior to founding Biomedical Instrumentation, Dr. Wodlinger held positions as Chief Engineer at Madsen Electronics, a leading supplier of audiology equipment, and as a Biomedical Engineer at the Wellesley Hospital, a 550-bed teaching hospital of the University of Toronto.
Dr. Wodlinger has a Ph.D. in Biomedical Engineering from the University of Toronto. He has numerous patents and publications. He is currently Chairman of the Board of Z-Tech Inc., a breast cancer detection company, and is a member of the Scientific Advisory Board for Vengrowth Capital Partners Advanced Life Sciences Fund.
